Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accumulated Expenses (2016 - 2025)

Seres Therapeutics' Accumulated Expenses history spans 11 years, with the latest figure at $4.4 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 74.92% year-over-year to $4.4 million; the TTM value through Sep 2025 reached $4.4 million, down 74.92%, while the annual FY2024 figure was $10.7 million, 52.38% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $4.4 million at Seres Therapeutics, up from $4.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $86.4 million in Q2 2024 and bottomed at $2.9 million in Q1 2021.
  • The 5-year median for Accumulated Expenses is $17.7 million (2024), against an average of $29.1 million.
  • The largest annual shift saw Accumulated Expenses soared 1009.74% in 2024 before it tumbled 95.1% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $45.1 million in 2021, then tumbled by 67.38% to $14.7 million in 2022, then skyrocketed by 53.03% to $22.5 million in 2023, then plummeted by 52.38% to $10.7 million in 2024, then crashed by 58.54% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Accumulated Expenses are $4.4 million (Q3 2025), $4.2 million (Q2 2025), and $6.2 million (Q1 2025).